With fresh in­vestor cash in hand, Volas­tra part­ners with Mi­crosoft to de­vel­op metasta­t­ic can­cer bio­mark­er plat­form

De­spite a suite of in­no­va­tions in on­co­log­ic ther­a­py, metasta­t­ic can­cer re­mains one of the lead­ing killers of US pa­tients, and the un­der­ly­ing dri­vers of its growth are still lit­tle known. A West Harlem biotech is look­ing at one po­ten­tial path to solv­ing metas­ta­sis, and now it’s work­ing with a high-pro­file part­ner to speed its ef­forts.

Volas­tra has closed an ex­pand­ed $44 mil­lion Se­ries A and iced a deal with Mi­crosoft to de­vel­op new dig­i­tal tools to iden­ti­fy bio­mark­ers for can­cer metas­ta­sis based on the com­pa­ny’s work study­ing chro­mo­so­mal in­sta­bil­i­ty, the biotech said in a pair of re­leas­es Tues­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER